Denileukin diftitox: A concise clinical review

John W. Eklund, Timothy M. Kuzel*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations

Abstract

Denileukin diftitox (DAB389IL-2; Ontak®) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.

Original languageEnglish (US)
Pages (from-to)33-38
Number of pages6
JournalExpert review of anticancer therapy
Volume5
Issue number1
DOIs
StatePublished - Feb 1 2005

Keywords

  • Cutaneous T-cell lymphoma
  • DABIL-2
  • Denileukin diftitox
  • Diphtheria toxin
  • Fusion protein
  • Ontak®

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Denileukin diftitox: A concise clinical review'. Together they form a unique fingerprint.

Cite this